Herpes Simplex Virus Treatment Market, By Drug Type (Acyclovir, Valacyclovir, Famciclovir, and Other Drugs), By Route of Administration (Oral, Injection, and Topical), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Published In : Apr 2023

Code : CMI5631

Pages :171

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Herpes Simplex Virus Treatment Market: Key Developments

In January 2023, Molbio Diagnostics launched the Truenat HSV 1/2 for testing the herpes simplex virus. The test is approved by CDSCO and can provide sample-to-test results in an hour. The real-time PCR test works on the existing Truelab infrastructure and doesn' t require additional setup and equipment to run the test, making it possible to test at resource-limited settings.

In October 2021, United BioPharma collaborated with Shanghai Public Health Clinical Centre and Cheng Kung University' s Department of Microbiology and Immunology to investigate the efficacy of UB-621, a best-in-class long-acting medication for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2).

In July 2021, Rational Vaccines received the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) Innovation Passport for RVx201, a therapeutic vaccine developed for genital herpes resulting from the herpes simplex type 2 (HSV-2) virus.

In May 2020, Shionogi & Co. and Genocea Biosciences Inc. teamed up to develop herpes simplex vaccine. Under a material transfer agreement, Shionogi will evaluate certain herpes simplex virus type 2, antigens from Genocea' s GEN-003 program.

Global Herpes Simplex Virus Treatment Market: Key Companies Insights